New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2013
12:27 EDTAMGNEarnings Preview: Amgen shares up sharply in July ahead of Q2 results
Amgen (AMGN) is scheduled to report Q2 earnings after the market close on Tuesday, July 30, with a conference call scheduled for 5:00 pm ET. Amgen is an American-based multinational biopharmaceutical company headquartered in Thousand Oaks, California. EXPECTATIONS: Analysts are looking for EPS of $1.74 on revenue of $4.49B, according to First Call. The consensus range for EPS is $1.66-$1.83 on revenue of $4.35B-$4.57B. LAST QUARTER: Amgen reported Q1 EPS of $1.96 against estimates of $1.84 on revenue of $4.2B, against estimates of $4.37B. STREET RESEARCH: On May 1, Amgen was upgraded to Conviction Buy from Neutral at Goldman. Goldman upgraded Amgen based on valuation and its late-stage pipeline which is highly innovative and has the potential to replace key biologic franchises that are coming off patent. Goldman raised its price target to $130 from $100 on Amgen shares. PRICE ACTION: Amgen shares have rallied approximately 15% since early July and are up 0.9% on the day to $110.35
News For AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
16:03 EDTAMGNAmgen reports Q4 EPS $2.16, consensus $2.05
Subscribe for More Information
15:35 EDTAMGNNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Apple (AAPL), consensus $2.60; AT&T (T), consensus 55c; Amgen (AMGN), consensus $2.05; Yahoo (YHOO), consensus 29c; ACE (ACE), consensus $2.29; Stryker (SYK), consensus $1.45; Western Digital (WDC), consensus $2.10; Electronic Arts (EA), consensus 92c; Juniper (JNPR), consensus 31c; Total System Services (TSS), consensus 53c; Freescale Semiconductor (FSL), consensus 33c; Amdocs (DOX), consensus 81c; VMware (VMW), consensus $1.07; International Game Technology (IGT), consensus 25c; United States Steel (X), consensus 87c; Cytec (CYT), consensus 61c.
12:57 EDTAMGNEarnings Preview: Amgen's Kyprolis, Prolia sales key for Q4 results
Subscribe for More Information
January 21, 2015
10:16 EDTAMGNLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 15, 2015
16:04 EDTAMGNAmgen announces new data from Phase 2 PEAK, Phase 3 PRIME studies
Amgen announced new data from the Phase 2 PEAK and Phase 3 PRIME studies that support the first-line use of Vectibix in combination with Folfox, an oxaliplatin-based chemotherapy regimen, in patients with wild-type RAS metastatic colorectal cancer. In an exploratory analysis from the PEAK study, treatment with Vectibix compared to Avastin resulted in a "significantly higher proportion" of patients with earlier tumor shrinkage at week eight, 64% vs. 45%, respectively, and among responding patients, a longer duration of response, 11.4 vs. 8.5 months, respectively, and greater depth of response . Overall response rates appeared to be similar between Vectibix and Avastin. This is consistent with observed overall survival and progression-free survival (PFS) rates, and with data previously reported, Amgen said. It added, "While the primary analysis from PEAK showed similar ORR between the Vectibix- and bevacizumab-based regimens, this exploratory analysis demonstrates that Vectibix produces early, sustained anti-tumor activity, which may in part explain the OS and PFS benefits seen with Vectibix versus bevacizumab in this trial."
07:59 EDTAMGNAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
January 13, 2015
12:55 EDTAMGNAmgen repeats FY15 adjusted EPS view $9.05-$9.40, consensus $9.29
Subscribe for More Information
12:40 EDTAMGNAmgen off highs after Express Scripts CEO talks PCSK9 costs
Subscribe for More Information
07:42 EDTAMGNJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use